Navigation Links
JacksonWhite Files Overtime Lawsuit Against Sunovion Pharmaceuticals

MESA, Ariz., March 16, 2012 /PRNewswire/ -- On March 8, attorneys at the Arizona law firm of JacksonWhite filed a collective action lawsuit against Sunovion Pharmaceuticals for failure to pay its employees the overtime wages to which they are entitled under the Fair Labor Standards Act (FLSA). The Complaint was filed in the United States District Court for the District of Oregon on behalf of all Sunovion pharmaceutical reps employed in the U.S. from March 2009 until the present.

Michael Pruitt is lead counsel for the individual and collective plaintiffs. "This case is about seeing to it that Sunovion employees are fully compensated for the long hours it takes to meet Sunovion's demands," said Pruitt. Sunovion requires its employees to work well over forty hours per week, and it has never paid its employees overtime wages, despite the overtime requirement that is clearly defined and outlined by federal law. Sunovion's willful violation of this law could entitle Sunovion reps to damages of up to two times the amount of overtime wages that Sunovion should have paid them over the past three years.

Sunovion's policy of withholding overtime wages is by no means unique. Industry-wide, multi-billion dollar pharmaceutical companies have knowingly misclassified their pharmaceutical reps as exempt from the FLSA's overtime requirement. The tide seems to be turning, however, as reps have banded together en masse to assert their legal rights. In January 2012, for instance, a Federal Court in New York preliminarily approved a 99 million dollar settlement for Novartis reps that were unlawfully deprived of overtime wages. 

In addition to the Sunovion lawsuit, JacksonWhite has a collective action lawsuit against GlaxoSmithKline that is presently pending review at the U.S. Supreme Court. The attorneys working on the case are cautiously optimistic about its outcome, and they expect that a favorable decision by the justices could lead to a revolution in the way in which pharmaceutical reps are compensated. If the Supreme Court sides with reps in the Glaxo case, it is that much more likely that Sunovion reps will also prevail on their claim.

Importantly, Sunovion reps can only participate in this collective action lawsuit if they provide a written consent to join. And given that there is a statute of limitations in these types of cases, reps who delay are subject to losing damages to which they might otherwise be entitled. The attorneys at JacksonWhite are interested in speaking with Sunovion reps about opting in to this collective action. Reps who work for other companies might also be able to join a legal action, or file a new action against the company for which they work. For more information, contact JacksonWhite at 480-779-0993 or visit

SOURCE Jackson White P.C.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Major Repligen (Nasdaq: RGEN) Shareholder Files Amended 13D
2. Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control
3. Essentialis Files Two New Patent Applications for Investigational Compound DCCR
4. Bionovo Files Registration Statement for Offering of Convertible Preferred Stock and Warrants
5. ReBuilder (RBRM) Files Complaints Against Stock Traders
6. Acella Pharmaceuticals, LLC, Files Abbreviated New Drug Application (ANDA) With the U.S. Food & Drug Administration
7. Natural Alternatives International, Inc. Files Patent Infringement Claim Against DNP International Co., Inc.
8. Department of Justice files consent decree of permanent injunction against Ranbaxy
9. Oramed Pharmaceuticals Files US Patent Application for Combination Oral Treatment of Diabetes
10. Intellect Neurosciences Files Appeal in Europe in Response to Opposition Proceedings Instituted by Elan Pharmaceuticals and Wyeth/Pfizer
11. Amherst-Based Pharmaceutical Company Files Federal Lawsuit Accusing Competitor of False Claims Regarding the Efficacy of Infasurf®, its Life-Saving Respiratory Drug for Premature Infants
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: ... License Application (BLA) with the United States ... ABP 501, a biosimilar candidate to Humira ® ... biosimilar application submitted to the FDA and represents Amgen,s ... Sean E. Harper , M.D., executive vice president ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
(Date:11/25/2015)... 25, 2015 On Tuesday, November 24, ... trial against Wright Medical Technology, Inc. for product ... metal-on-metal hip implant device, awarded $11 million in ... week trial and three days of deliberations, the ... was defectively designed and unreasonably dangerous, and that ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... ... for mental health and wellness consultation, has collaborated with Women’s Web – ... their reader’s queries on topics on mental and emotional well-being relationship, life ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... where preparing the perfect dish and pleasing the palates of attendees is of ... bringing a dish to a seasonal get-together, give these recipes a try this ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director ... about hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for ... and fuller hair, without the need for surgery, prescription pills, or topical foams. ...
(Date:11/25/2015)... ... November 25, 2015 , ... According to an article published November ... more widely heralded as a breakthrough for performing hernia repairs. The article explains that ... surgery is that it can greatly reduce the pain that a patient might otherwise ...
(Date:11/25/2015)... Raton, Florida (PRWEB) , ... November 25, 2015 ... ... diagnostic testing for physicians and athletic programs, launches new Wimbledon Athletics ... importance of testing young athletes for unsuspected cardiac abnormalities. About 2,000 people under ...
Breaking Medicine News(10 mins):